Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11923803 | 0.88 | POLB (0.40) | FFAR3POLBLMNATSHRALDH1A1 | |
| SCHEMBL2055539 | 0.80 | FFAR3 (0.62) | FFAR3POLBLMNATSHRALDH1A1 | |
| SCHEMBL6865583 | 0.78 | — | — | |
| SCHEMBL2055525 | 0.78 | FFAR3 (0.35) | FFAR3POLBLMNATSHRALDH1A1 | |
| SCHEMBL811021 | 0.78 | — | — | |
| SCHEMBL17574280 | 0.76 | ALDH1A1 (0.48) | FFAR3LMNAALDH1A1SMN1; SMN2GAA | |
| SCHEMBL13954105 | 0.76 | FFAR3 (0.48) | FFAR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL14407687 | 0.76 | ALDH1A1 (0.48) | FFAR3LMNAALDH1A1SMN1; SMN2GAA | |
| SCHEMBL12626878 | 0.76 | ALDH1A1 (0.48) | FFAR3LMNAALDH1A1SMN1; SMN2GAA | |
| SCHEMBL6866082 | 0.76 | ALDH1A1 (0.48) | FFAR3LMNAALDH1A1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295087-A1 | AGONISTS OF ROR GAMMAt | BRISTOL MYERS SQUIBB CO (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295087-A1 | AGONISTS OF ROR GAMMAt | BRISTOL MYERS SQUIBB CO (US) | 2023-09-21 | — | — | US | disclosed |
| WO-2020231766-A1 | AGONISTS OF ROR GAMMAt | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-19 | — | — | WO | disclosed |
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-9458171-B2 | Pyrrolidinyl sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295087-A1 | AGONISTS OF ROR GAMMAt | RORB, RORA, RORC | FFAR3 248/4885POLB 2605/4885LMNA 3526/4885 |
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | RORC, RORB, RORA | FFAR3 663/4885POLB 2057/4885LMNA 4085/4885 |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | RORC, RORB, RORA | FFAR3 424/4885POLB 2312/4885LMNA 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.